Activity
Revolutionizing Drug Discovery: AI-Driven Solutions for Efficient and Personalized Treatments
Artificial Intelligence (AI) in Drug Discovery, Machine Learning (ML) for Drug Development, Quantum Computing in Pharmaceutical Research, Personalized Medicine, Efficient Drug Discovery Processes, AI-Driven Target Identification and Validation, Quantum Machine Learning (QML) for Drug Discovery
WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.
Psyence Biomed to Acquire Clairvoyant Therapeutics, Expanding Psilocybin-Based Therapeutic Pipeline
Psilocybin, Psyence Biomed, Clairvoyant Therapeutics, Acquisition, Alcohol Use Disorder (AUD), Clinical Trials, Psychedelic Therapeutics
Connect Biotech Scales Back in China, Reassesses Strategy for Asthma Drug to Compete with Dupixent
Connect Biotech, China workforce reduction, Dupixent rival, asthma drug strategy, biotech industry
EU High Court Rules in Favor of Illumina in Grail Acquisition Appeal
Illumina, Grail, European Court of Justice, Acquisition, Antitrust Litigation, Liquid Biopsy
Recursion’s Phase 2 Trial for Cerebral Cavernous Malformation Shows Limited Efficacy Despite Meeting Safety Goals
Recursion Pharmaceuticals, Phase 2 trial, cerebral cavernous malformation (CCM), REC-994, safety and tolerability, efficacy data, FDA meeting
Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings
Catalent, Q4 Results, Novo Holdings, Acquisition, Pharmaceutical, Biotech, Consumer Health
Catalent’s Revival: Are the Dark Days Behind It Ahead of Novo Holdings Acquisition?
Catalent, Novo Holdings, acquisition, pharmaceutical industry, revenue boost, dark days, revival
Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network
Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals
LEO Pharma’s Acquisition of Timber Pharmaceuticals’ Assets Faces Setback Due to Late-Stage Study Failure
LEO Pharma, Timber Pharmaceuticals, TMB-001, congenital ichthyosis, late-stage study failure, asset acquisition